Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients with ST-Segment Elevation Myocardial Infarction
The role of sacubitril/valsartan in patient with heart failure (HF) is established. Whether sacubitril/valsartan plays a role in improving outcomes in patients after ST-segment elevation myocardial infarction (STEMI) is unknown. The current study aims to comparing the efficacy and safety of sacubitril/valsartan versus ramipril in post-STEMI patients. Patients presenting with STEMI were randomized to receive either sacubitril/valsartan or ramipril after primary percutaneous coronary intervention (PCI).
Source: The American Journal of Cardiology - Category: Cardiology Authors: Ahmed Rezq, Marwan Saad, Mostafa El Nozahi Source Type: research
More News: Angioplasty | Cardiology | Coronary Angioplasty | Diovan | Heart | Heart Attack | Heart Failure | Percutaneous Coronary Intervention | Study